Related Experiment Videos

[High blood pressure and coronary heart disease. Are there new therapeutic options?]

Wolfgang Motz1

  • 1Herz- und Diabeteszentrum Mecklenburg-Vorpommern, Klinikum Karlsburg, Herz-Kreislaufforschung, Universität Witten/Herdecke, Witten/Herdecke. WMotz@t-online.de

Herz
|May 29, 2004
PubMed

Insights

Arterial hypertension is a major risk factor for coronary artery disease and organ damage. Effective treatment requires vascular protection, with ACE-inhibitors as first-line therapy, often combined with other agents and statins.

Area of Science:

  • Cardiology
  • Hypertension Research
  • Vascular Medicine

Context:

  • Arterial hypertension is a primary risk factor for coronary artery disease (CAD).
  • Hypertension causes organ damage like left ventricular hypertrophy and coronary microangiopathy, worsening myocardial ischemia in CAD patients.
  • Vascular protection is crucial in managing hypertension.

Purpose:

  • To review the role of vascular protection in antihypertensive treatment.
  • To evaluate current first-line antihypertensive agents and combination therapies.
  • To highlight the importance of statins in hypertensive patients.

Summary:

  • Angiotensin-converting enzyme (ACE) inhibitors are recommended as first-line treatment for hypertension due to their vascular and myocardial protective effects.
  • Angiotensin II receptor blockers (ARBs) show no superior efficacy compared to ACE inhibitors.
  • Combination therapy with calcium channel blockers, beta-blockers, or diuretics may be necessary if ACE inhibitors alone are insufficient.
  • Statins are recommended for hypertensive patients, regardless of LDL cholesterol levels, to reduce cardiovascular morbidity and mortality.

Impact:

  • Antihypertensive treatment must extend beyond blood pressure reduction to include vascular and organ protection.
  • ACE inhibitors are a cornerstone of modern hypertension management.
  • Statins play a vital role in comprehensive cardiovascular risk reduction for hypertensive individuals.

Related Concept Videos

Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...